S&P 500   4,295.93 (-0.09%)
DOW   33,544.77 (-0.36%)
QQQ   357.60 (-0.11%)
AAPL   170.55 (-0.08%)
MSFT   315.47 (+0.58%)
META   300.29 (-1.21%)
GOOGL   130.60 (-1.29%)
AMZN   126.68 (+0.56%)
TSLA   248.49 (+0.86%)
NVDA   434.96 (+0.94%)
NIO   9.00 (+1.01%)
BABA   86.83 (+1.51%)
AMD   103.39 (+0.61%)
T   14.97 (-0.27%)
F   12.43 (-1.04%)
MU   67.99 (+4.28%)
CGC   0.79 (-2.53%)
GE   110.64 (-1.51%)
DIS   80.68 (+0.69%)
AMC   7.90 (+1.41%)
PFE   33.13 (+3.24%)
PYPL   58.17 (-0.02%)
NFLX   376.17 (-0.05%)
S&P 500   4,295.93 (-0.09%)
DOW   33,544.77 (-0.36%)
QQQ   357.60 (-0.11%)
AAPL   170.55 (-0.08%)
MSFT   315.47 (+0.58%)
META   300.29 (-1.21%)
GOOGL   130.60 (-1.29%)
AMZN   126.68 (+0.56%)
TSLA   248.49 (+0.86%)
NVDA   434.96 (+0.94%)
NIO   9.00 (+1.01%)
BABA   86.83 (+1.51%)
AMD   103.39 (+0.61%)
T   14.97 (-0.27%)
F   12.43 (-1.04%)
MU   67.99 (+4.28%)
CGC   0.79 (-2.53%)
GE   110.64 (-1.51%)
DIS   80.68 (+0.69%)
AMC   7.90 (+1.41%)
PFE   33.13 (+3.24%)
PYPL   58.17 (-0.02%)
NFLX   376.17 (-0.05%)
S&P 500   4,295.93 (-0.09%)
DOW   33,544.77 (-0.36%)
QQQ   357.60 (-0.11%)
AAPL   170.55 (-0.08%)
MSFT   315.47 (+0.58%)
META   300.29 (-1.21%)
GOOGL   130.60 (-1.29%)
AMZN   126.68 (+0.56%)
TSLA   248.49 (+0.86%)
NVDA   434.96 (+0.94%)
NIO   9.00 (+1.01%)
BABA   86.83 (+1.51%)
AMD   103.39 (+0.61%)
T   14.97 (-0.27%)
F   12.43 (-1.04%)
MU   67.99 (+4.28%)
CGC   0.79 (-2.53%)
GE   110.64 (-1.51%)
DIS   80.68 (+0.69%)
AMC   7.90 (+1.41%)
PFE   33.13 (+3.24%)
PYPL   58.17 (-0.02%)
NFLX   376.17 (-0.05%)
S&P 500   4,295.93 (-0.09%)
DOW   33,544.77 (-0.36%)
QQQ   357.60 (-0.11%)
AAPL   170.55 (-0.08%)
MSFT   315.47 (+0.58%)
META   300.29 (-1.21%)
GOOGL   130.60 (-1.29%)
AMZN   126.68 (+0.56%)
TSLA   248.49 (+0.86%)
NVDA   434.96 (+0.94%)
NIO   9.00 (+1.01%)
BABA   86.83 (+1.51%)
AMD   103.39 (+0.61%)
T   14.97 (-0.27%)
F   12.43 (-1.04%)
MU   67.99 (+4.28%)
CGC   0.79 (-2.53%)
GE   110.64 (-1.51%)
DIS   80.68 (+0.69%)
AMC   7.90 (+1.41%)
PFE   33.13 (+3.24%)
PYPL   58.17 (-0.02%)
NFLX   376.17 (-0.05%)
NYSE:NNVC

NanoViricides (NNVC) Stock Forecast, Price & News

$1.36
-0.05 (-3.55%)
(As of 12:18 PM ET)
Compare
Today's Range
$1.36
$1.42
50-Day Range
$1.25
$1.70
52-Week Range
$1.04
$2.00
Volume
3,762 shs
Average Volume
58,618 shs
Market Capitalization
$15.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.25

NNVC stock logo

About NanoViricides (NYSE:NNVC) Stock

NanoViricides, Inc., a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Monkeypox Treatment for Monkeypox virus; Adenovirus 71 Treatment for severe pediatric hepatitis caused by Adenovirus 71 or related viruses; and HerpeCide Program Expansion Drug project that develops broad-spectrum nanoviricide drugs against different herpes viruses for different indications. The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. The company was founded in 2005 and is based in Shelton, Connecticut.

NNVC Price History

NNVC Stock News Headlines

NanoViricides (NYSE:NNVC) Now Covered by Analysts at StockNews.com
NanoViricides (NYSE:NNVC) Now Covered by StockNews.com
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
NNVC: NanoViricides Begins Clinical Trial of NV-CoV-2
NanoViricides progressing well with new Covid study
Successful Options Trading Begins With…
Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!
Why Are NanoViricides Shares Gaining Today
See More Headlines
Receive NNVC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NanoViricides and its competitors with MarketBeat's FREE daily newsletter.

NNVC Company Calendar

Last Earnings
11/15/2021
Today
9/29/2023
Fiscal Year End
6/30/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.25
High Stock Price Forecast
$5.25
Low Stock Price Forecast
$5.25
Forecasted Upside/Downside
+272.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,110,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.00 per share

Miscellaneous

Free Float
11,123,000
Market Cap
$16.41 million
Optionable
Optionable
Beta
1.17
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Anil R. Diwan Ph.D. (Age 64)
    Exec. Chairman, Pres, CEO & Sec.
    Comp: $400k
  • Ms. Meeta R. Vyas B.S. (Age 64)
    M.B.A., SB, MBA, Chief Financial Officer
    Comp: $129.6k
  • Dr. Randall W. Barton Ph.D. (Age 76)
    Chief Scientific Officer & Chief Regulatory Officer













NNVC Stock - Frequently Asked Questions

Should I buy or sell NanoViricides stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NanoViricides in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NNVC shares.
View NNVC analyst ratings
or view top-rated stocks.

What is NanoViricides' stock price forecast for 2023?

1 Wall Street research analysts have issued 1 year price targets for NanoViricides' shares. Their NNVC share price forecasts range from $5.25 to $5.25. On average, they anticipate the company's share price to reach $5.25 in the next year. This suggests a possible upside of 272.3% from the stock's current price.
View analysts price targets for NNVC
or view top-rated stocks among Wall Street analysts.

How have NNVC shares performed in 2023?

NanoViricides' stock was trading at $1.11 at the start of the year. Since then, NNVC shares have increased by 27.0% and is now trading at $1.41.
View the best growth stocks for 2023 here
.

How were NanoViricides' earnings last quarter?

NanoViricides, Inc. (NYSE:NNVC) released its quarterly earnings results on Monday, November, 15th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.03.

When did NanoViricides' stock split?

NanoViricides's stock reverse split on the morning of Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What is NanoViricides' stock symbol?

NanoViricides trades on the New York Stock Exchange (NYSE) under the ticker symbol "NNVC."

How do I buy shares of NanoViricides?

Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NanoViricides' stock price today?

One share of NNVC stock can currently be purchased for approximately $1.41.

How much money does NanoViricides make?

NanoViricides (NYSE:NNVC) has a market capitalization of $16.41 million. The company earns $-8,110,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.

How can I contact NanoViricides?

NanoViricides' mailing address is 1 Controls Drive, Shelton CT, 06484. The official website for the company is www.nanoviricides.com. The company can be reached via phone at (203) 937-6137, via email at clyburn@tradigitalir.com, or via fax at 203-859-5095.

This page (NYSE:NNVC) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -